참고문헌
- Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16. https://doi.org/10.1161/01.CIR.96.2.509
- Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53. https://doi.org/10.1016/S0140-6736(97)06031-5
- Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgentcare setting. J Am Coll Cardiol 2001;37:379-85. https://doi.org/10.1016/S0735-1097(00)01156-6
- Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. https://doi.org/10.1056/NEJMoa020233
- Yoo BS, Kim WJ, Jung HS, et al. The clinical experiences of B-type natriuretic peptide blood concentrations for diagnosis in congestive heart failure: the single hospital experience based on the large clinical database. Korean Circ J 2004;34:684-92. https://doi.org/10.4070/kcj.2004.34.7.684
- Sutton TM, Stewart RA, Gerber IL, et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003;41:2280-7. https://doi.org/10.1016/S0735-1097(03)00486-8
- Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34. https://doi.org/10.1016/0002-9343(92)90011-Y
- Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000;35:1256-62. https://doi.org/10.1016/S0735-1097(00)00515-5
- Choe HM, Yoo BS, Ryu HY, et al. The early changing pattern of the Btype natriuretic peptide concentration and its significance as a prognostic marker after acute myocardial infarction. Korean Circ J 2006;36: 526-34. https://doi.org/10.4070/kcj.2006.36.7.526
- Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-63. https://doi.org/10.1056/NEJMoa031994
- Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002;87:131-5. https://doi.org/10.1136/heart.87.2.131
- McDonagh TA, McDonald K, Maisel AS. Screening for asymptomatic left ventricular dysfunction using B-type natriuretic Peptide. Congest Heart Fail 2008;14(4 Suppl):5-8. https://doi.org/10.1111/j.1751-7133.2008.08283.x
- Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82. https://doi.org/10.1016/S0735-1097(02)02059-4
- Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600. https://doi.org/10.1161/01.CIR.0000112582.16683.EA
- Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 2003;108:13-6. https://doi.org/10.1161/01.CIR.0000081657.83724.A7
- Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51. https://doi.org/10.1136/heart.89.7.745
- Segawa T, Nakamura M, Itai K, Onoda T, Okayama A, Hiramori K. Plasma B-type natriuretic peptide levels and risk factors for congestive heart failure in a Japanese general population. Int Heart J 2005;46: 465-75. https://doi.org/10.1536/ihj.46.465
- Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 2008;101:9-15.
- Krauser DG, Chen AA, Tung R, Anwaruddin S, Baggish AL, Januzzi JL Jr. Neither race nor gender influences the usefulness of aminoterminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail 2006;12:452-7. https://doi.org/10.1016/j.cardfail.2006.04.005
- Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-Btype natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008;101:29-38. https://doi.org/10.1016/j.amjcard.2007.11.017
- Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide?: how well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-76. https://doi.org/10.1093/eurheartj/ehi410
- Marz W, Tiran B, Seelhorst U, et al. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 2007;53:1075-83. https://doi.org/10.1373/clinchem.2006.075929
- Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004;27:1929-35. https://doi.org/10.2337/diacare.27.8.1929
- Hildebrandt P, Richards AM. Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol 2008;101:21-4.
- Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006;27:3004-10. https://doi.org/10.1093/eurheartj/ehl406
- Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R. Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol 2008;102:469-74. https://doi.org/10.1016/j.amjcard.2008.03.082
- Wang HS, Yoo BS, Chung IY, et al. Is B-type natriuretic peptide (BNP) measurement useful test for diagnosing systolic heart failure in patients with moderate to severe renal insufficiency? Korean Circ J 2005;35: 897-903. https://doi.org/10.4070/kcj.2005.35.12.897
- Almirez R, Protter AA. Clearance of human brain natriuretic peptide in rabbits: effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther 1999;289:976-80.
- Coste J, Jourdain P, Pouchot J. A gray zone assigned to inconclusive results of quantitative diagnostic tests: application to the use of brain natriuretic peptide for diagnosis of heart failure in acute dyspneic patients. Clin Chem 2006;52:2229-35. https://doi.org/10.1373/clinchem.2006.072280
- Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008;38:101-13. https://doi.org/10.1111/j.1445-5994.2007.01454.x
- Austin MJ, Heneghan MA. Multiple biomarkers and cardiovascular risk. N Engl J Med 2008;359:760-1. https://doi.org/10.1056/NEJMc081303
- Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Longterm stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004;42:942-4.
피인용 문헌
- Renal dysfunction as a risk factor for painless myocardial infarction: results from Korea Acute Myocardial Infarction Registry vol.101, pp.10, 2010, https://doi.org/10.1007/s00392-012-0461-1
- The need for multicentre cardiovascular clinical trials in Asia vol.10, pp.6, 2010, https://doi.org/10.1038/nrcardio.2013.49